CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance

Stav Sapoznik, Sarit Aviel-Ronen, Keren Bahar-Shany, Oranit Zadok, Keren Levanon

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Delayed diagnosis of ovarian cancer, as well as high recurrence rates and lack of personalized therapy options, are among the causes for poor survival figures. Much effort is made towards developing new therapeutic possibilities, however predictive biomarkers are still unavailable. CCNE1 amplification, occurring in ~20% of the high grade serous ovarian tumors, was previously proposed as a marker for platinum resistance and poor prognosis as well as for CDK2 inhibition. The current study aimed to examine the role of CCNE1 positive-immunostain as a predictor of first-line taxane-platinum chemoresistance. We evaluated matched pre- vs. postneoadjuvant chemotherapy tumor samples and correlated the degree of pathological response to treatment with CCNE1 expression levels. Our results indicate that CCNE1 immunohistochemistry does not predict taxane-platinum chemoresistance in ovarian cancer patients. Further research is required in order to enable personalized adjuvant treatment, in cases where poor pathological response is achieved after the neoadjuvant phase.

Original languageEnglish
Pages (from-to)62240-62247
Number of pages8
Issue number37
StatePublished - 1 Sep 2017
Externally publishedYes


  • CCNE1
  • Chemoresistance
  • Neoadjuvant chemotherapy
  • Ovarian cancer
  • Predictive biomarker


Dive into the research topics of 'CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance'. Together they form a unique fingerprint.

Cite this